Key Highlights

  • Absci shares are trading down 9.94% to $9.25 in Wednesday's session, extending Wednesday's pullback.
  • The decline comes with no company-specific negative news, amid a broader development-stage biotech selloff.
  • Investors are weighing risk ahead of the company's first hair-loss trial readout, expected this quarter.
  • The stock remains up sharply year to date despite today's slide, within a 52-week range of $2.24 to $12.06.

A Pullback Driven by Positioning, Not New Bad News

Absci (NASDAQ:ABSI) shares are trading sharply lower in Wednesday's session, with no company-specific negative announcement behind the move. The decline instead appears tied to investor caution ahead of the company's first readout from its ABS-201 hair-loss trial, expected this quarter, alongside a broader selloff across development-stage biotechnology stocks.

A Key Readout Looms for the Company's AI-Designed Antibody

ABS-201 is an investigational anti-prolactin receptor antibody engineered using the company's generative AI drug-design platform, currently being evaluated in the Phase 1/2a HEADLINE trial for pattern hair loss. Data from that trial is expected to inform dosing for a separate planned Phase 2 trial, named STORYLINE, evaluating the same antibody for endometriosis, a condition the company says affects roughly one in ten women of reproductive age. The company recently detailed plans to recruit approximately 150 patients across 10 or more countries for the endometriosis study, with initiation anticipated in mid-2027.

Today's decline extends a pullback following a sharp run-up earlier this month, leaving the stock vulnerable to "sell the news" dynamics as the hair-loss data approaches.

The Hair-Loss Readout Is the Next Real Catalyst

With safety, tolerability, and pharmacokinetic data from the HEADLINE trial still pending, the stock's near-term direction is likely to hinge on that readout rather than today's trading pattern. Despite the sharp daily decline, shares remain well above their 52-week low of $2.24, reflecting the stock's considerable year-to-date gain heading into the catalyst window.